Key Details
Price
$32.85Annual ROE
-24.65%Beta
2.01Events Calendar
Next earnings date:
Feb 07, 2025Recent quarterly earnings:
Oct 23, 2024Recent annual earnings:
Feb 07, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) finished at $38.88, which is a decrease of 1.09% compared to the day before.
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.
NEW YORK , Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
In this video, I will cover the recent updates regarding Viking Therapeutics (VKTX 1.26%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Viking Therapeutics (VKTX 4.30%) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's share price eroded by 24% in December, primarily on the back of a rival's aggressive move into a potentially very lucrative segment of the pharmaceutical market.
FAQ
- What is the primary business of Viking Therapeutics?
- What is the ticker symbol for Viking Therapeutics?
- Does Viking Therapeutics pay dividends?
- What sector is Viking Therapeutics in?
- What industry is Viking Therapeutics in?
- What country is Viking Therapeutics based in?
- When did Viking Therapeutics go public?
- Is Viking Therapeutics in the S&P 500?
- Is Viking Therapeutics in the NASDAQ 100?
- Is Viking Therapeutics in the Dow Jones?
- When was Viking Therapeutics's last earnings report?
- When does Viking Therapeutics report earnings?
- Should I buy Viking Therapeutics stock now?